Amedeo Smart

Free Medical Literature Service


 

Amedeo

Migraine

  Free Subscription

Articles published in
Lancet
    November 2023
  1. DODICK DW, Goadsby PJ, Schwedt TJ, Lipton RB, et al
    Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
    Lancet. 2023 Nov 15:S0140-6736(23)01683-5. doi: 10.1016/S0140-6736(23)01683.
    >> Share

    July 2023
  2. POZO-ROSICH P, Ailani J, Ashina M, Goadsby PJ, et al
    Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jul 26:S0140-6736(23)01049-8. doi: 10.1016/S0140-6736(23)01049.
    >> Share

  3. HAANES KA, Edvinsson L
    Atogepant, the first oral preventive treatment for chronic migraine.
    Lancet. 2023 Jul 26:S0140-6736(23)01462-9. doi: 10.1016/S0140-6736(23)01462.
    >> Share

    March 2021
  4. ASHINA M, Katsarava Z, Do TP, Buse DC, et al
    Migraine: epidemiology and systems of care.
    Lancet. 2021 Mar 25. pii: S0140-6736(20)32160.
    >> Share

  5. ASHINA M, Buse DC, Ashina H, Pozo-Rosich P, et al
    Migraine: integrated approaches to clinical management and emerging treatments.
    Lancet. 2021 Mar 25. pii: S0140-6736(20)32342.
    >> Share

  6. ASHINA M, Terwindt GM, Al-Karagholi MA, de Boer I, et al
    Migraine: disease characterisation, biomarkers, and precision medicine.
    Lancet. 2021 Mar 25. pii: S0140-6736(20)32162.
    >> Share

    December 2020
  7. CROOP R, Lipton RB, Kudrow D, Stock DA, et al
    Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2020 Dec 15. pii: S0140-6736(20)32544.
    >> Share

  8. EDVINSSON L
    Oral rimegepant for migraine prevention.
    Lancet. 2020 Dec 15. pii: S0140-6736(20)32624.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016